Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study.

MLA

Kiladjian, Jean-Jacques, et al. “Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80 Years: An Interim Analysis of the EXELS Study.” Clinical Drug Investigation, vol. 33, no. 1, Jan. 2013, pp. 55–63. EBSCOhost, https://doi.org/10.1007/s40261-012-0042-0.

APA

Kiladjian, J.-J., Besses, C., Griesshammer, M., Gugliotta, L., Harrison, C., Coll, R., Smith, J., & Birgegård, G. (2013). Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study. Clinical Drug Investigation, 33(1), 55–63. https://doi.org/10.1007/s40261-012-0042-0

Chicago

Kiladjian, Jean-Jacques, Carlos Besses, Martin Griesshammer, Luigi Gugliotta, Claire Harrison, Ruth Coll, Jonathan Smith, and Gunnar Birgegård. 2013. “Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80 Years: An Interim Analysis of the EXELS Study.” Clinical Drug Investigation 33 (1): 55–63. doi:10.1007/s40261-012-0042-0.